Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you offer adjuvant treatment to a Stage IB NSCLC, margins negative but with findings of STAS (tumor spread through airway spaces)?
STAS has been associated with poorer prognosis. NCCN has no guidelines for this adverse feature.
Related Questions
At what age do you stop LDCT chest for lung cancer screening?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
Is there any data supporting the use of osimertinib in patients with L858R-mutated lung cancer who had a durable response to prior EGFR TKI therapy, and who progressed 1-2 years after discontinuation of other EGFR inhibitors?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
How do you decide between neoadjuvant or perioperative chemoimmunotherapy, as per Checkmate 816 or KEYNOTE-671, for early-stage NSCLC?
How do you treat Stage IIIC T4N3 NSCLC?
What is your approach to obtain tissue diagnosis for a patient with a lung primary and spine metastasis?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?